Angelika Schmitt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Angelika Schmitt has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Angela D.M. Kashuba
1 shared publication- Anil K. Malhotra
Division of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY 11004, USA
1 shared publication AnnCatherine Van Lone
1 shared publicationBernard Lerer
1 shared publication- Chin Bin Eap
Unit of Pharmacogenetics and Clinical Psychopharmacology, Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, University of Lausanne, Prilly, Switzerland
1 shared publication Colleen M. Niswender
1 shared publication
Latest Publications
- Open Access
- 1 January 2009
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 3, 26
Living in a dangerous world: the shaping of behavioral profile by early environment and 5-HTT genotype
Anxiety and anxiety disorders are influenced by both, environmental and genetic factors. One genetic factor under scrutiny for anxiety disorders is the genetically encoded variation of the serotonin transporter (5-HTT). The aim of this study was to elucidate the effects of a threatening environment during early phases of life on anxiety-like (ANX) and exploratory behavior (EXP) in adult mice, varying in serotonin transporter (5-HTT) genotype. For this purpose, pregnant and lactating 5-HTT +/− dams were repeatedly exposed to olfactory cues of unfamiliar adult males by introducing small amounts of soiled bedding to their home cage. These stimuli signal the danger of infanticide and simulate a threatening environment. Control females were treated with neutral bedding. The offspring (5-HTT +/+, +/−, −/−) were examined for their ANX and EXP. The main results were: (1) a main effect of genotype existed, with 5-HTT −/− showing higher levels of ANX and lower levels of EXP than 5-HTT +/− and wildtypes. (2) When mothers had lived in a threatening environment, their offspring showed increased ANX and reduced EXP compared to controls. (3) These effects were most pronounced in 5-HTT −/− mice. By applying a new ecologically relevant paradigm we conclude: If 5-HTT +/− mothers live in a threatening environment during pregnancy and lactation, their offspring behavioral profile will, in principle, be shaped in an adaptive way preparing the young for an adverse environment. This process is, however, modulated by 5-HTT genotype, bearing the risk that individuals with impaired serotonergic neurotransmission (5-HTT −/−) will develop an exaggerated, potentially pathological level of anxiety from gene × environment interactions.
- 1 January 2009
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 3, 26
Open AccessLiving in a dangerous world: the shaping of behavioral profile by early environment and 5-HTT genotype
Anxiety and anxiety disorders are influenced by both, environmental and genetic factors. One genetic factor under scrutiny for anxiety disorders is the genetically encoded variation of the serotonin transporter (5-HTT). The aim of this study was to elucidate the effects of a threatening environment during early phases of life on anxiety-like (ANX) and exploratory behavior (EXP) in adult mice, varying in serotonin transporter (5-HTT) genotype. For this purpose, pregnant and lactating 5-HTT +/− dams were repeatedly exposed to olfactory cues of unfamiliar adult males by introducing small amounts of soiled bedding to their home cage. These stimuli signal the danger of infanticide and simulate a threatening environment. Control females were treated with neutral bedding. The offspring (5-HTT +/+, +/−, −/−) were examined for their ANX and EXP. The main results were: (1) a main effect of genotype existed, with 5-HTT −/− showing higher levels of ANX and lower levels of EXP than 5-HTT +/− and wildtypes. (2) When mothers had lived in a threatening environment, their offspring showed increased ANX and reduced EXP compared to controls. (3) These effects were most pronounced in 5-HTT −/− mice. By applying a new ecologically relevant paradigm we conclude: If 5-HTT +/− mothers live in a threatening environment during pregnancy and lactation, their offspring behavioral profile will, in principle, be shaped in an adaptive way preparing the young for an adverse environment. This process is, however, modulated by 5-HTT genotype, bearing the risk that individuals with impaired serotonergic neurotransmission (5-HTT −/−) will develop an exaggerated, potentially pathological level of anxiety from gene × environment interactions.
- 20 August 2002
- Published by Cambridge University Press (CUP)
Pharmacogenetics of Psychotropic Drugs
Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.
- 20 August 2002
- Published by Cambridge University Press (CUP)
Pharmacogenetics of Psychotropic Drugs
Pharmacogenetics and pharmacogenomics are areas of significant importance at the interface of molecular genetics and psychopharmacology, with implications for drug development and clinical practice. This 2002 book provides a conceptual framework for understanding and studying the pharmacogenetics of psychotropic drugs, reviews advances in the field, and describes the established findings. Coverage extends to antipsychotics, antidepressants, mood stabilising, cognitive-enhancing and anxiolytic drugs. Chapters also examine the interface of pharmacogenetics with substance dependence and brain imaging, and consider its impact on the biotechnology and pharmaceutical industries. This book defines the young field of pharmacogenetics as it applies to psychotropic drugs, and is therefore of interest to all clinicians and researchers working in this field.